Predict your next investment

Public-Private Partnership
BUSINESS PRODUCTS & SERVICES
medcbrn.org

See what CB Insights has to offer

Investments

1

About Medical CBRN Defense Consortium

The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.

Medical CBRN Defense Consortium Headquarter Location

California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Medical CBRN Defense Consortium Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Medical CBRN Defense Consortium Rank

Latest Medical CBRN Defense Consortium News

SwRI Receives $9.9 Million to Develop Nerve Agent Antidote

Mar 24, 2020

Southwest Research Institute has received funding from the Medical CBRN Defense Consortium (MCDC) administered by Advanced Technology International to develop a nerve agent antidote for emergency use on the battlefield or to protect public health . The use of nerve agents continues to be a significant threat to both military and civilian populations. This prototype medication could serve as a countermeasure against a nerve agent attack. SwRI will lead the development of the antidote under the $9.9 million, five-year program, and will collaborate with University of Pittsburgh on the synthesis and compound design, through the support of the Defense Threat Reduction Agency (DTRA). “This antidote improves on the current standard of care, importantly, its ability to reverse the effects of the toxin in the central nervous system,” said SwRI’s Dr. Jonathan Bohmann, a principal scientist in SwRI’s Pharmaceutical and Bioengineering Department. “The antidote will eventually be administered through an autoinjector, which allows for rapid and effective treatment in the field. It would work much like an Epinephrine Auto-Injector or EpiPen® administered during a severe allergy attack. The initial goal of the project is to support our warfighters; however, this treatment could also eventually be administered for civilian use.” In the design of the new medication, SwRI will use a computer-based drug design software platform called Rhodium™. SwRI developed Rhodium™, a proprietary docking simulation software program tool, to enhance drug design and safety while reducing costs and speeding up development time. The Institute offers Rhodium as a service to clients. SwRI is one of 193 industry, government and nonprofit organizations supporting the medical countermeasures sector in MCDC. This sector was founded to support U.S. Department of Defense needs in areas of infectious diseases, chemical threats and other medical countermeasures for military personnel. SwRI’s Chemistry and Chemical Engineering Division is ISO 9001:2015 certified, meeting international quality standards for product development from initial design through production and service. SwRI scientists support drug development from discovery to clinical trials in FDA-inspected Current Good Manufacturing Practice facilities. Rhodium supports drug development and screening for antibiotics as well as preventative treatments such as vaccines. The software also predicts adverse drug reactions and side effects. For more information, visit https://www.swri.org/industries/pharmaceutical-development .

Medical CBRN Defense Consortium Investments

1 Investments

Medical CBRN Defense Consortium has made 1 investments. Their latest investment was in Southwest Research Institute as part of their Grant - III on March 3, 2020.

CBI Logo

Medical CBRN Defense Consortium Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/24/2020

Grant - III

Southwest Research Institute

$9.9M

Yes

5

Date

3/24/2020

Round

Grant - III

Company

Southwest Research Institute

Amount

$9.9M

New?

Yes

Co-Investors

Sources

5

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.